FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Gullans Steven R. Ph.D.					2. Issuer Name and Ticker or Trading Symbol Gemphire Therapeutics Inc. [GEMP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last)	,	rst) (PARK DRIVE	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/22/2018								'	-	r (give title	ıt & (Other (
SUITE 401					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	•															X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(SI	tate) (Zip)																	
		Tab	le I - N	on-Deriv	ative S	Sec	urities	Ac	quired, [)isp	osed o	of, or E	enef	icial	ly Owne	d				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date,			Code (Instr.			rities Acced Of (D)			Securit Benefic Owned	ies cially	Forn (D) o	n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amoun	t (A	or	Price				tr. 4)	(Instr. 4)	
		Ta	able II						uired, Dis s, options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/		4. Fransaction Code (Instr. 3)				6. Date Exe Expiration (Month/Day	Date	Amount of		of es ing ve		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisable		piration te	Amo or Num of Title Shar		nber						
Employee Stock Option (right to buy)	\$5.56	05/22/2018 ⁽¹⁾			A		50,000		(2)	04/	/30/2028	Common Stock	50,	000	\$0	50,000		D		
Employee Stock Option (right to buy)	\$5.56	05/22/2018 ⁽¹⁾			A		50,000		(3)	04/	/30/2028	Common Stock	50,	000	\$0	50,000		D		

Explanation of Responses:

- 1. The option was approved by the board of directors of the issuer on May 1, 2018, subject to stockholder approval of an amendment to the equity incentive plan under which the option was granted. The issuer's stockholders approved such amendment on May 22, 2018.
- 2. The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date. The option includes an early exercise provision, subject to the issuer's right of repurchase with respect to any unvested shares of common stock.
- 3. 50,000 shares underlying the option will vest if and when the issuer's common stock achieves a specified volume weighted average closing price for 30 consecutive days on or before December 31, 2019. 50,000 remaining shares underlying the option award are subject to a performance condition and will vest on the date that the first patient in the first Phase 3 clinical trial in a non-orphan indication receives the first dose of geneabene if such event occurs on or before December 31, 2019. The option includes an early exercise provision, subject to the issuer's right of repurchase with respect to any unvested shares of common stock.

/s/ Stephanie Swan, by Power of Attorney

05/24/2018

ctly

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.